AUTHOR=Zhang Hua , Yan Shu , Zhan Yan , Ma Sheng , Bian Yicong , Li Shaorong , Tian Junjun , Li Guangze , Zhong Dafang , Diao Xingxing , Miao Liyan TITLE=A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans JOURNAL=Frontiers in Pharmacology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1116073 DOI=10.3389/fphar.2023.1116073 ISSN=1663-9812 ABSTRACT=
SHR6390 (dalpiciclib) is a selective and effective cyclin-dependent kinase (CDK) 4/6 inhibitor and an effective cancer therapeutic agent. On 31 December 2021, the new drug application was approved by National Medical Product Administration (NMPA). The metabolism, mass balance, and pharmacokinetics of SHR6390 in 6 healthy Chinese male subjects after a single oral dose of 150 mg [14C]SHR6390 (150 µCi) in this research. The